ARS Pharmaceuticals (SPRY) EPS (Basic) (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted EPS (Basic) of -$0.97 for Q1 2026, down 118.82% sequentially from -$0.44 in Q4 2025, and down 153.74% YoY from $1.8 in Q1 2025.
Powered by 
Analysis
ARS Pharmaceuticals (SPRY) EPS (Basic) (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported EPS (Basic) for 7 years, with the latest figure at -$0.97 in Q1 2026.
- Quarterly EPS (Basic) fell 153.74% year-over-year to -$0.97 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.78 (down 120.2% YoY) and the FY2025 annual result came in at -$1.74, down 2206.35% from the prior year.
- EPS (Basic) slipped to -$0.97 in Q1 2026 per SPRY's latest filing, from -$0.44 in the prior quarter.
- Over five years, EPS (Basic) peaked at $0.49 in Q4 2024 and troughed at -$418.21 in Q1 2023.
- A 5-year average of -$58.36 and a median of -$0.7 in 2024 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2023 and 2024: EPS (Basic) tumbled 126507.86% in 2023, then soared 563.49% in 2024.
- Over 5 years, EPS (Basic) stood at -$0.38 in 2022, then surged by 72.23% to -$0.11 in 2023, then jumped by 563.49% to $0.49 in 2024, then tumbled by 190.56% to -$0.44 in 2025, then slumped by 118.82% to -$0.97 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.97, -$0.44, and -$1.14 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | ARS Pharmaceuticals | 561.12 Mn | 417.27 Mn | 20.81 Mn | -0.64 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.64 |
| Mar 31, 2026 | -0.63 |
| Dec 31, 2025 | -0.42 |
| Sep 30, 2025 | -0.54 |
| Jun 30, 2025 | -0.49 |
| Mar 31, 2025 | -0.38 |
| Dec 31, 2024 | 0.49 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -0.16 |
| Mar 31, 2024 | -0.14 |
| Dec 31, 2023 | -0.11 |
| Sep 30, 2023 | -0.19 |
| Jun 30, 2023 | -0.22 |
| Mar 31, 2023 | -0.20 |
| Dec 31, 2022 | -0.38 |
| Sep 30, 2022 | -0.19 |
| Jun 30, 2022 | -0.18 |
| Mar 31, 2022 | -0.20 |
| Dec 31, 2021 | 1.34 |
| Sep 30, 2021 | -0.65 |